Company Analysis
Sign in

Palisade Bio, Inc. (PALI)

Nasdaq: PALI · Biological Products, (No Diagnostic Substances) · Carlsbad, CA · filing with the SEC since 2006
Full chart Alerts Compare
Grade4.8
◀ Past 1.4● Present 4.4▶ Future 7.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

29 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Palisade Bio, Inc.’s names, not what it holds today.

Patents granted
29
29 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
32
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name, a subsidiary
By yearGrantedApplications published
'08'09'10'11'12'13'14'15'16'17'18'19'20'21'22
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
NEURALSTEM, INC. a former name
US, as the owner printed on each patent
23 granted
18 published
Leading BioSciences, Inc. a subsidiary
US, as the owner printed on each patent
6 granted
2 published
Leading Biosciences, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
Neuralstem, Inc. a former name
named as the applicant on its applications, in US
0 granted
5 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 13, 202211,439,611Administration of serine protease inhibitors to the stomachPharmaceuticalsLeading BioSciences, Inc.
Dec 21, 202111,202,768Compositions and methods for treating and preventing adhesions and ileusPharmaceuticalsLeading BioSciences, Inc.
Sep 21, 202111,123,317Compositions for the treatment of autodigestionPharmaceuticalsLeading BioSciences, Inc.
Sep 15, 202010,772,861Administration of serine protease inhibitors to the stomachPharmaceuticalsLeading BioSciences, Inc.
Jul 7, 202010,702,555Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereofPharmaceuticalsNEURALSTEM, INC.
Sep 17, 201910,413,534Amelioration of certain deficiencies due to strokePharmaceuticalsNEURALSTEM, INC.
Jun 18, 201910,322,115Amelioration of neural deficits associated with diabetesPharmaceuticalsNEURALSTEM, INC.
May 14, 201910,286,010Methods of treating neurodegenerative conditionsPharmaceuticalsNEURALSTEM, INC.
Oct 3, 20179,775,821Compositions for the treatment of autodigestionPharmaceuticalsLeading BioSciences, Inc.
Sep 5, 20179,750,769Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereofPharmaceuticalsNEURALSTEM, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 24, 20222022/0370389ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACHPharmaceuticalsLeading BioSciences, Inc.
Mar 17, 20222022/0079903COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ADHESIONS AND ILUESPharmaceuticalsLeading Biosciences, Inc.
Feb 24, 20222022/0054439COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTIONPharmaceuticalsLeading BioSciences, Inc.
Jun 17, 20212021/0177789ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACHPharmaceuticalsLeading Biosciences, Inc. · patent 11,439,611 granted from it
Apr 15, 20212021/0106579AMELIORATION OF COGNITIVE AND MOTOR DEFICITS ASSOCIATED WITH ALZHEIMER'SPharmaceuticalsNEURALSTEM, INC.
Oct 15, 20202020/0323803COMPOSITIONS AND METHODS FOR GLUCOSE CONTROLPharmaceuticalsLeading Biosciences, Inc.
May 16, 20192019/0142829AMELIORATION OF ANGELMAN'S SYNDROME DEFICIENCIESMedical technologyNEURALSTEM, INC.
Apr 25, 20192019/0117604COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ADHESIONS AND ILEUSPharmaceuticalsLeading Biosciences, Inc. · patent 11,202,768 granted from it
Aug 16, 20182018/0228787AMELIORATION OF CERTAIN DEFICIENCIES DUE TO STROKEPharmaceuticalsNEURALSTEM, INC. · patent 10,413,534 granted from it
Apr 19, 20182018/0104240AMELIORATION OF RADIATION-INDUCED COGNITIVE DYSFUNCTIONPharmaceuticalsNEURALSTEM, INC.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PALI · research, not advice